These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32579898)

  • 21. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
    Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
    Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 Employs Multiple Mechanisms To Resist Cas9/Single Guide RNA Targeting the Viral Primer Binding Site.
    Wang Z; Wang W; Cui YC; Pan Q; Zhu W; Gendron P; Guo F; Cen S; Witcher M; Liang C
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30068653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel gRNA design pipeline to develop broad-spectrum CRISPR/Cas9 gRNAs for safe targeting of the HIV-1 quasispecies in patients.
    Sullivan NT; Dampier W; Chung CH; Allen AG; Atkins A; Pirrone V; Homan G; Passic S; Williams J; Zhong W; Kercher K; Desimone M; Li L; C Antell G; Mell JC; Ehrlich GD; Szep Z; Jacobson JM; Nonnemacher MR; Wigdahl B
    Sci Rep; 2019 Nov; 9(1):17088. PubMed ID: 31745112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA-guided gene editing of the murine gammaherpesvirus 68 genome reduces infectious virus production.
    Foreman HC; Kirillov V; Paniccia G; Catalano D; Andrunik T; Gupta S; Krug LT; Zhang Y
    PLoS One; 2021; 16(6):e0252313. PubMed ID: 34086743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Negative Feedback Regulation of HIV-1 by Gene Editing Strategy.
    Kaminski R; Chen Y; Salkind J; Bella R; Young WB; Ferrante P; Karn J; Malcolm T; Hu W; Khalili K
    Sci Rep; 2016 Aug; 6():31527. PubMed ID: 27528385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.
    Roychoudhury P; De Silva Feelixge H; Reeves D; Mayer BT; Stone D; Schiffer JT; Jerome KR
    BMC Biol; 2018 Jul; 16(1):75. PubMed ID: 29996827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.
    Kayesh MEH; Amako Y; Hashem MA; Murakami S; Ogawa S; Yamamoto N; Hifumi T; Miyoshi N; Sugiyama M; Tanaka Y; Mizokami M; Kohara M; Tsukiyama-Kohara K
    Virus Res; 2020 Dec; 290():198191. PubMed ID: 33049308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.
    Dampier W; Sullivan NT; Mell JC; Pirrone V; Ehrlich GD; Chung CH; Allen AG; DeSimone M; Zhong W; Kercher K; Passic S; Williams JW; Szep Z; Khalili K; Jacobson JM; Nonnemacher MR; Wigdahl B
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):950-960. PubMed ID: 29968495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA.
    Zhu W; Lei R; Le Duff Y; Li J; Guo F; Wainberg MA; Liang C
    Retrovirology; 2015 Feb; 12():22. PubMed ID: 25808449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex.
    Saayman SM; Lazar DC; Scott TA; Hart JR; Takahashi M; Burnett JC; Planelles V; Morris KV; Weinberg MS
    Mol Ther; 2016 Mar; 24(3):488-98. PubMed ID: 26581162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptional and posttranscriptional regulation of HIV-1 gene expression.
    Karn J; Stoltzfus CM
    Cold Spring Harb Perspect Med; 2012 Feb; 2(2):a006916. PubMed ID: 22355797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elimination of infectious HIV DNA by CRISPR-Cas9.
    Das AT; Binda CS; Berkhout B
    Curr Opin Virol; 2019 Oct; 38():81-88. PubMed ID: 31450074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication.
    Huelsmann PM; Hofmann AD; Knoepfel SA; Popp J; Rauch P; Di Giallonardo F; Danke C; Gueckel E; Schambach A; Wolff H; Metzner KJ; Berens C
    BMC Biotechnol; 2011 Jan; 11():4. PubMed ID: 21223573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of small molecule modulators of HIV-1 Tat and Rev protein accumulation.
    Balachandran A; Wong R; Stoilov P; Pan S; Blencowe B; Cheung P; Harrigan PR; Cochrane A
    Retrovirology; 2017 Jan; 14(1):7. PubMed ID: 28122580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection.
    Wollebo HS; Bellizzi A; Kaminski R; Hu W; White MK; Khalili K
    PLoS One; 2015; 10(9):e0136046. PubMed ID: 26360417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A lentiviral vector that activates latent human immunodeficiency virus-1 proviruses by the overexpression of tat and that kills the infected cells.
    Macías D; Oya R; Saniger L; Martín F; Luque F
    Hum Gene Ther; 2009 Nov; 20(11):1259-68. PubMed ID: 19604078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection.
    Wang Q; Liu S; Liu Z; Ke Z; Li C; Yu X; Chen S; Guo D
    Virus Res; 2018 May; 250():21-30. PubMed ID: 29625148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The RRE-Rev Module Has No Effect on the Packaging Efficiency of Cas9 and Gag Proteins into NanoMEDIC Virus-like Particles.
    Kruglova NA; Komkov DS; Mazurov DV; Shepelev MV
    Dokl Biol Sci; 2023 Dec; 513(Suppl 1):S45-S50. PubMed ID: 38472686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile?
    De Silva Feelixge HS; Stone D; Roychoudhury P; Aubert M; Jerome KR
    ACS Infect Dis; 2018 Jun; 4(6):871-880. PubMed ID: 29522311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
    Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
    Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.